John Valliant - 05 Jan 2023 Form 4 Insider Report for Fusion Pharmaceuticals Inc. (FUSN)

Role
Chief Executive Officer, Director
Signature
/s/Maria Stahl as Attorney-in-Fact for John Valliant
Issuer symbol
FUSN
Transactions as of
05 Jan 2023
Transactions value $
$0
Form type
4
Filing time
09 Jan 2023, 05:46:32 UTC
Previous filing
27 Apr 2022
Next filing
05 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +500,000 $0 500,000 05 Jan 2023 Common Stock 500,000 $3.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in 48 equal monthly installments beginning on February 5, 2023.